Clinical trial
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or…
NCT00112723 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00112723 |
|---|---|
| Title | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma |
| Official title | A Phase I/II Study of Flavopiridol Administered as a 30-Minute Bolus Followed by a 4-Hour Infusion in Lymphomas and Multiple Myeloma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma and 18 more |
| Intervention type | Drug |
| Interventions | alvocidib |
| Enrollment | 46 |
| Start date | Dec 1, 2005 |
| Primary completion | Feb 1, 2011 |
| Completion | Nov 1, 2015 |
| First posted | Jun 3, 2005 |
| Last update posted | Aug 8, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: